{"nctId":"NCT00532155","briefTitle":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","startDateStruct":{"date":"2007-09"},"conditions":["Carcinoma","Non Small Cell Lung"],"count":913,"armGroups":[{"label":"Aflibercept/Docetaxel","type":"EXPERIMENTAL","interventionNames":["Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","Drug: Docetaxel (Taxotere®)","Drug: Dexamethasone (pre- and post-medication for docetaxel)"]},{"label":"Placebo/Docetaxel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Docetaxel (Taxotere®)","Drug: Dexamethasone (pre- and post-medication for docetaxel)"]}],"interventions":[{"name":"Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Docetaxel (Taxotere®)","otherNames":[]},{"name":"Dexamethasone (pre- and post-medication for docetaxel)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological/cytological proven locally advanced or metastatic non-small cell lung cancer\n* Disease progression during or after one, and only one, prior anticancer therapy which is platinum-based for advanced or metastatic disease\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2\n* Adequate renal, liver and bone marrow functions\n\nExclusion Criteria:\n\n* Squamous histology/cytology\n* Less than 28 days elapsed from prior treatment with radiotherapy, surgery, or chemotherapy to the time of randomization\n* Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to \\> 25% of bone marrow\n* Prior docetaxel treatment\n* Uncontrolled hypertension\n\nThe above information was not intended to contain all considerations relevant to participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS was time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, overall survival time was censored at the last date the participant was known to be alive, or the study cutoff date, whichever was earlier. The cut-off date for the OS was date when 687 deaths were observed.\n\nOS was estimated from Kaplan-Meier Curves.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.41","spread":null},{"groupId":"OG001","value":"10.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as the time interval between the date of randomization and the time of occurrence of the first radiological tumor progression detected by a computer tomography (CT) scan and /or by Magnetic Resonance Imaging (MRI); or death due to any cause; whichever was earlier. Participants without disease progression were censored at the earliest date between their last valid tumour assessment and the data cutoff date.\n\nPFS was estimated from Kaplan-Meier Curves.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.11","spread":null},{"groupId":"OG001","value":"5.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria","description":"Participants with OR were those who had a confirmed complete response \\[CR\\] or a confirmed partial response \\[PR\\], based on RECIST criteria, in which\n\n* CR refected the disappearance of all tumor lesions (with no new tumors)\n* PR reflected a pre-defined decrease in tumor burden - a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD\n* OR was CR + PR The response rate was the percent of participants with a response.\n\nTo determine a response, tumors were assessed by the investigators using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"38.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)","description":"HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies (appetite, fatigue, cough, dyspnea, hemoptysis and pain), and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. The LCSS total score was defined as the mean of the 9 items of the scale, each scored between 0 (for best outcome) to 100 (for worst outcome).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.52","spread":"17.03"},{"groupId":"OG001","value":"31.54","spread":"18.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.50","spread":"16.72"},{"groupId":"OG001","value":"30.54","spread":"16.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.67","spread":"16.24"},{"groupId":"OG001","value":"29.61","spread":"16.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.82","spread":"18.34"},{"groupId":"OG001","value":"36.07","spread":"18.81"}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)","description":"HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies, and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. ABSI was the mean score for the six major lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis and pain), each scored between 0 (for best outcome) to 100 (for worst outcome).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.17","spread":"16.30"},{"groupId":"OG001","value":"28.24","spread":"16.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.23","spread":"15.93"},{"groupId":"OG001","value":"27.05","spread":"15.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.52","spread":"15.22"},{"groupId":"OG001","value":"26.19","spread":"16.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.73","spread":"17.26"},{"groupId":"OG001","value":"31.19","spread":"18.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":159,"n":453},"commonTop":["Alopecia","Fatigue","Stomatitis","Diarrhoea","Decreased appetite"]}}}